Abstract | METHODS: Thirty studies with 1308 eyes were identified and included in this study. The primary outcome measures were best-corrected visual acuity (BCVA), and secondary outcomes were optical coherence tomography characteristics and polyp regression rates. The pooled results were calculated by the random-effect or fixed-effect model according to the heterogeneity of the data. RESULTS: Despite a large standard deviation in means (SMD) improvement for BCVA and central retinal thickness (CRT) in the conbercept group, there was no statistically significant difference in the other outcomes compared to ranibizumab and aflibercept. However, there was a greater polyp regression rate in the conbercept group at 12 months. CONCLUSIONS:
|
Authors | Yimin Wang, Mengxi Shen, Jinwei Cheng, Xiaodong Sun, Peter K Kaiser |
Journal | Journal of ophthalmology
(J Ophthalmol)
Vol. 2020
Pg. 4924053
( 2020)
ISSN: 2090-004X [Print] United States |
PMID | 32855818
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2020 Yimin Wang et al. |